Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
long term economic burden, neurologic, psychiatric, international, multi-ethnic, SLE, criteria, classification, damage, lupus, prognosis, autoimmune diseases, biological therapy, glucocorticoids, systemic lupus erythematosus, health-related quality of life, interferon signature, SLEDAI, transcriptomic, patient-reported outcome, fatigue, disease activity, mediation analysis
Jourde-Chiche N, et al. Ann Rheum Dis. 2022. Epub ahead of print. doi:10.1136/annrheumdis-2022-222435.
Non-inferiority of maintenance immunosuppressive therapy (IST) discontinuation after 2‒3 years was not demonstrated for renal relapse, in proliferative lupus nephritis (LN).
N Engl J Med. 2020;383(12):1117–28.
LN occurs in 25–60% of patients with SLE. However, patients with LN are often excluded from clinical trials of SLE therapies.
